2025.08.04
Apeloa showcases first-class CDMO services at CMC-China Pharma Expo
2025.07.02
Apeloa puts sustainability centre stage at US GC&E conference
2025.06.26
Apeloa underscores innovation and modernity at CPHI China 2025
2025.05.12
Apeloa’s first ESG Report Released
2025.04.16
Apeloa Jiayuan successfully completed a U.S. FDA cGMP inspection
2024.11.14
APELOA proudly introduces our latest API product, Gabapentin
2024.10.09
APELOA has obtained FDA approval for Amantadine Hydrochloride Tablets (100mg)
2024.09.13
Grand Opening of the Apeloa Pharma Solutions R&D Center in Billerica, MA
2024.08.28
Dr. Yong-Li Zhong as Chief Technology Officer, Chemistry
2024.08.19
2024 Interim Report Highlights
2024.07.30
APELOA has obtained FDA approval for our Metoprolol Succinate Extended-Release Tablets
2024.07.08
Apeloa is among the Top 5 in the China Pharmaceutical CDMO Companies
